Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus) Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...

Zylö Therapeutics Closes $5.225 Million Series B Financing GREENVILLE, SC, June 03, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series...

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...

Zylö and Grapefruit Forge Partnership That Promises to Disrupt the Topical Cannabis Market The Z-pod™ delivery system will help make Hourglass™ by Grapefruit a game-changer GREENVILLE, SC, July 28, 2020 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the transformational...